Guiren Pharma

Guiren Pharma, officially Guiren Pharmaceutical Technology (Shanghai) Co., Ltd., is a clinical-stage biopharmaceutical company based in Shanghai, China, and a key subsidiary of Qyuns Therapeutics. The company focuses on the discovery and development of innovative antibody-based therapies for autoimmune diseases, inflammatory conditions, and oncology. Its lead candidate, GR-1802 (also known as QX005N), is a humanized monoclonal antibody targeting the IL-4Rα receptor, currently in Phase 3 clinical trials for atopic dermatitis and Phase 2 for asthma. Other notable programs include GR-1801, a Claudin 18.2-targeted antibody for solid tumors, and GR-1603, an IL-17A inhibitor for ankylosing spondylitis. Guiren Pharma leverages an integrated R&D platform to advance its pipeline from early-stage discovery through global clinical development.